Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Simultaneous...

    Simultaneous Dual-troponin testing safely rules out MI very early

    Written by Medha Baranwal Baranwal Published On 2018-05-05T19:15:55+05:30  |  Updated On 5 May 2018 7:15 PM IST
    Simultaneous Dual-troponin testing safely rules out MI  very early

    New strategies combining the concentrations of both cardiac troponin type I (cTnI) and type T (cTnT) may allow for early and safe rule-out of acute myocardial infarction (AMI), according to a new study published in the journal Circulation. But the combined-troponin testing does not seem helpful for the rule-in of AMI.


    The study was conducted by Noreen van der Linden, MD, Ph.D., Maastricht University Medical Center, the Netherlands, and colleagues, evaluate the diagnostic performance of combinations of high sensitivity (hs) cTnI and hs-cTnT for the early diagnosis of AMI. This was based on a primary cohort of 2225 patients suspected of having MI and a similar 2537-patient validation cohort, both drawn from other studies.


    cTnI and cTnT are subtypes of troponin protein which are very specific and scientific indicators of damage to the heart muscle (myocardium). They are measured in the blood to differentiate between unstable angina and MI in people with acute coronary syndrome or chest pain.


    For finding the relevance of the cardiac troponins for ealry diagnosis of AMI, the diagnostic performance of combining hs-cTnI and hs-cTnT concentrations were evaluated in a large multicenter diagnostic study of patients with suspected AMI. The optimal rule out and rule in thresholds were externally validated in a second large multicenter diagnostic study. The proportion of patients eligible for early rule out was compared with the ESC 0/1 and 0/3 hour algorithms.


    Based on the study, following inferences were made:




    • combining hs-cTnI and hs-cTnT concentrations did not consistently increase overall diagnostic accuracy as compared with the individual isoforms

    • the combination (hs-cTnI and hs-cTnT) improved the proportion of patients meeting criteria for very early rule-out

    • application of optimized cut-off values using the sum and product of hs-cTnI and hs-cTnT concentrations led to an increase in the proportion ruled-out after a single blood draw to 34-41% in the original

    • use of a combination algorithm showed comparable results for rule out cohort 99.9% and rule-in original cohort 74.4%.


    "The major benefit of combining cardiac troponin T and I is the increase in number of patients eligible for safe rule-out after one single blood draw at presentation, from approximately 10% to 40% of patients," several authors of the study wrote to theheart.org .



    "This will cause a decrease in the number of patients who need consecutive blood draws for cardiac troponin tests," which "may have profound consequences for clinical practice, since it could help overcome unnecessary resource use, overcrowding of the emergency department, and anxiety among patients."

    They pointed out that patients in the two cohorts entered their international studies consecutively and so are likely "representative of the overall patient population presenting to an emergency department with symptoms suggestive of chest pain."


    Used individually, the high-sensitivity troponin assays have shown great safety in MI rule-out algorithms, "but few patients can be ruled out within an hour," observed James A. de Lemos, MD, University of Texas Southwestern Medical Center, Dallas, in an interview. Many more can safely go home within 3 hours after serial testing.








    The dual-troponin strategy of the current analysis, he said, "is conceptually interesting, like much of what this group does," he said, agreeing that it has potential for expanding the proportion of patients in whom MI can be safely ruled out very early.


    The strategy could potentially be considered in Europe, which is "about 6 or 7 years ahead of the US with high-sensitivity troponin," noted de Lemos, who was not involved in the study. But here in the United States, "We have to get our heads around one high-sensitivity troponin before we start thinking about using two of them in the same patient."


    "New strategies combining hs-cTnI and hs-cTnT concentrations may significantly increase the number of patients eligible for very early and safe rule-out, but do not seem helpful for the rule-in of AMI," concluded that authors of the study.





    For further information click on the link: https://doi.org/10.1161/CIRCULATIONAHA.117.032003




    cardiac troponincardiac troponin type Icardiac troponin type TCirculationdiagnosis of AMIdiagnosis of MIdiagnosis of myocardial infarctionDr Noreen van der LindenDr. James A. de Lemosearly diagnosis of myocardial infarctionJames A. de Lemosjournal CirculationMImyocardial infarctionNoreen van der Lindenrule-in of AMIrule-out of AMItroponins
    Source : With inputs from Circulation

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok